Survival during lung injury requires a coordinated program of damage limitation and rapid repair. CD34 is a cell surface sialomucin expressed by epithelial, vascular, and stromal cells that promotes cell adhesion, coordinates inflammatory cell recruitment, and drives angiogenesis. To test whether CD34 also orchestrates pulmonary damage and repair, we induced acute lung injury in wild-type (WT) and Cd34 2/2 mice by bleomycin administration. We found that Cd34 2/2 mice displayed severe weight loss and early mortality compared with WT controls. Despite equivalent early airway inflammation to WT mice, CD34-deficient animals developed interstitial edema and endothelial delamination, suggesting impaired endothelial function. Chimeric Cd34 2/2 mice reconstituted with WT hematopoietic cells exhibited early mortality compared with WT mice reconstituted with Cd34 2/2 cells, supporting an endothelial defect. CD34-deficient mice were also more sensitive to lung damage caused by influenza infection, showing greater weight loss and more extensive pulmonary remodeling. Together, our data suggest that CD34 plays an essential role in maintaining vascular integrity in the lung in response to chemical-and infection-induced tissue damage.
Although the adult lung has a robust capacity to regenerate after injury, dysregulation of normal wound-healing processes leads to fibrosis and loss of organ function. These observations have prompted extensive studies into identification of lung progenitor populations capable of facilitating lung repair (1, 2) . The cell surface sialomucin, CD34, is a widely used marker for the enrichment of primitive, multipotent hematopoietic cells for bone marrow (BM) transplantation (3, 4) . More recently, its utility as a marker for progenitor cells has been extended to nonhematopoietic subsets, including muscle satellite cells (5) , hair follicle stem cells (6) , multipotent stromal cells (7, 8) , bronchoalveolar stem cells (9, 10) , and lung-resident endothelial progenitors (11) . Because CD34 is highly expressed by multiple progenitor populations and down-regulated in differentiated states, it has been hypothesized that CD34 may play a role in cycling of undifferentiated precursors (12) , but functional studies instead suggest that CD34 is an important regulator of cell adhesion and chemotaxis. In lymphoid tissues, a distinct glycoform of CD34 is expressed by high endothelial venules, and serves as a ligand for L-selectin on lymphocytes, thereby mediating naive cell recruitment to lymph nodes (13) . Although this suggests that CD34 can, in some cases, facilitate adhesion, this glycoform of CD34 is exquisitely specific to rare high endothelial venules, and, thus, is unlikely to promote adhesion in other tissues. CD34 is also expressed by a number of hematopoietic subsets, including eosinophils (14, 15) , mast cells (14, 16, 17) , dendritic cell precursors (18) , fibrocytes, and circulating endothelial progenitors (19, 20) . Intriguingly, deletion of CD34 in mast cells results in homotypic aggregation, suggesting an alternate role as a blocker of adhesion (17) . We have also noted impaired chemokine-dependent migration of eosinophils, arguing for a role in facilitating cell mobility and chemotaxis. Consistent with these observations, Cd34 2/2 mice are resistant to a variety of inflammatory diseases, due to defective inflammatory cell recruitment to peripheral tissues (14, 15, 18, 21) . Although this suggests an important role for CD34 in inflammatory cell trafficking, its function on nonhematopoietic and structural cells during tissue remodeling remains unknown.
Because CD34 is expressed by cells thought to mediate lung regeneration (epithelia, endothelia, and mesenchyme), we have now investigated its function in two models of lung injury. Bleomycin (BLM) inhalation results in damage to pneumocytes and endothelia, and is characterized by an inflammatory phase and vascular leak, followed by the accumulation of extracellular matrix in the parenchyma, resulting in abnormal alveolar architecture and compromised function (1, 22, 23) . Based on the well documented contribution of chronic inflammation to dysregulated tissue repair, we speculated that Cd34 2/2 mice would be protected from the development of fibrosis. Surprisingly, we find that Cd34 2/2 mice are extremely sensitive to BLM-induced damage, and exhibit a higher incidence of morbidity and mortality than their wild-type (WT) counterparts. Ultrastructural analyses of BLM-treated Cd34 2/2 lungs reveal interstitial edema in the alveolar walls and delamination of endothelial cells from the basal lamina. Similar experiments with BM chimeric mice indicate that sensitivity to BLM is due to the selective loss of CD34 on nonhematopoietic cells. Moreover, Cd34 2/2 mice exhibited more pronounced evidence of epithelial remodeling in response to influenza infection. In aggregate, these studies argue that CD34 plays a protective role in maintaining vascular integrity and basal lamina adhesion, and thereby facilitates tissue repair.
Materials and Methods
Mice C57BL/6J (WT), Cd34 
Lung Injury Models
Mice were challenged with BLM (Pharmaceutical Partners of Canada) endotracheally at a dose of 2.5 or 5.0 U/kg, or intravenously at a dose of 1.6 U/mouse. Static lung elastance was measured by performing volume-regulated perturbations on anesthetized and tracheotomized mice using a flexiVent apparatus (SCIREQ, Montreal, QC, Canada) (24) . Mice were challenged intranasally with 2.90 3 10 3 50% egg infective dose (EID 50 ) of influenza A/strain PR8 (H1N1). Cytokines in bronchoalveolar lavage fluid (BALF) or lung homogenates were quantified using a V-plex multispot assay (Meso Scale Discoveries, Rockville, MD).
Histology and Immunohistochemistry
Formalin-fixed and paraffin-embedded lungs were cut into 5-mm sections for Masson's trichrome or hematoxylin and eosin staining. For immunostaining, lung sections underwent antigen retrieval and were stained using antibodies against CD34 (RAM34; eBiosciences, Waltham, MA), podocalyxin (AF1556; R&D Systems, Minneapolis, MN), green fluorescent protein (ab13970; Abcam, Cambridge, UK), vimentin (ab92547; Abcam), surfactant protein C (AB3786; Millipore, Billerica, MA), E-cadherin (E-cad; 36/E-cad; BD, Franklin Lakes, NJ), and keratin 5 (Krt5; Poly9059; Biolegend, San Diego, CA). Sections were then incubated with AlexaFluorconjugated antibodies and mounted using Prolong Gold Antifade with DAPI (Life, Waltham, MA). Optical z-stack images were captured on a Leica SP5X confocal microscope (Leica, Wetzlar, Germany) and morphometric analysis was performed using ImageJ (Bethesda, MD).
Assessment of Pulmonary Vascular Leak
Vascular leak was evaluated by a modified Miles assay, as described previously (25, 26) . Mice were injected intravenously with 20 mg/kg Evans blue dye (EBD). After 1 hour, mice were anesthetized by intraperitoneal injection of avertin, followed by perfusion with 2 mM EDTA PBS. After excision, lungs were transferred to formamide for EBD extraction. The optical density of formamide was read at 620 and 740 nm on a spectrophotometer; the amount of dye per gram of lung tissue was calculated using a lung-specific correction factor (25, 26) .
Transmission Electron Microscopy
Lungs were fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer. Tissues were processed as described previously (27) and imaged using an FEI Tecnai 12 Transmission Electron Microscope (Hillsboro, OR).
Flow Cytometry
BALF was collected by three tracheal instillations and aspirations of 1 ml PBS. Tissues were digested with collagenase D (1.5 U/ml) and dispase II (2.4 U/ml) (Roche, Basel, Switzerland) for 30 minutes. Samples were then incubated with anti-CD16/32 to block nonspecific antibody binding.
Fluorescence-conjugated antibodies to CD45 (I3/2), CD11c (N418), CD3e (145-2C11), CD8 (53.67), CD4 (GK1.5), B220 (RA3-6B2), Ly6B (7/4) (Abcam), SiglecF (E50-2440; eBiosciences), CD34 (RAM34; eBiosciences), CD31 (390; eBiosciences), PDGFRa (APA5; eBiosciences), Ly-6A/E (Sca-1) (D7; eBiosciences), and CD326 (EpCAM) (G8.8; eBiosciences) were used. For EdU uptake experiments, mice were given 1 mg EdU daily by intraperitoneal injections; 5-ethynyl-2'-deoxyuridine (EdU) detection was performed using the Click-IT assay kit (Life). Data were acquired on a BD LSRII and analyzed with FlowJo Software (Ashland, OR). All antibodies were generated in-house (University of British Columbia AbLab), unless otherwise indicated.
Statistical Analysis
Survival data are presented as Kaplan-Meier curves and analyzed with a log-rank test. Normality of the data was assessed using the Shapiro-Wilk test; Student's t test or Mann-Whitney test was used to determine significance. Statistical analyses were performed using Prism 5.0 (La Jolla, CA).
Results
Early Mortality, but Unaltered Fibrosis, in Cd34 2/2 Mice after BLM Challenge
To assess the role of CD34 in lung injury and fibrosis, Cd34 2/2 and WT mice were treated endotracheally with a single dose of BLM. Strikingly, after administration of 5.0 or 2.5 U/kg of BLM (endotracheally), Cd34 2/2 mice showed a significant dosedependent increased frequency of mortality compared with WT controls ( Figures 1A  and 1B) . Nearly all mortality in Cd34 2/2 mice at the 2.5-U/kg-BLM dose occurred before Day 10. Because the onset of fibrosis in this model is known to occur at approximately 2 weeks after tracheal administration of BLM (23) , these data suggest that early morbidity is associated with the acute exudative phase of the disease, and independent of fibrosis. To further corroborate Cd34 2/2 mouse sensitivity to BLM in a systemic treatment regime, we assessed animal response after intravenous administration of 1.6 U/mouse BLM. Again, Cd34 2/2 mice experienced significantly greater weight loss than WT controls, with nearly all Cd34 2/2 animals reaching their humane endpoint by Day 6 ( Figure 1C ). In summary, CD34 plays a protective role in BLM-induced lung injury before the development of fibrosis.
Although there was a clear increase in early mortality in Cd34 2/2 mice, sufficient numbers of these mice tolerated the lower dose of BLM to permit the evaluation of lung fibrosis 21 days after treatment. Quantitative analyses of Masson's trichrome-stained lung sections revealed similar degrees of fibrotic remodeling in WT and Cd34 2/2 animals ( Figures 1D and  1E ). Moreover, static lung elastance was similar in BLM-treated WT and Cd34
2/2
animals, suggesting that loss of CD34 does not alter this functional outcome of fibrosis ( Figure 1F ). To eliminate the possibility of a biased assessment of fibrosis selectively in mice that survived initial lung damage, we evaluated WT and Cd34 2/2 mice after endotracheal treatment with a lower BLM dose (1.25 U/kg) to ensure 100% survival by Day 18 after treatment. Again, no significant differences in fibrotic indices were observed between WT and Cd34
animals (see Figure E1 in the online supplement). We conclude that loss of CD34 exacerbates the early phase of BLMinduced injury, but has no effect on the later fibrotic responses. 
ORIGINAL RESEARCH CD34 Does Not Alter Acute Lung Inflammation in Response to BLM
Because we have previously observed attenuated allergic inflammatory responses in the lungs of Cd34 2/2 mice (14, 18), we evaluated whether the acute inflammation that occurs after BLM treatment was altered by loss of CD34. Total CD45 1 leukocyte numbers in the BALF were similar in both WT and Cd34 2/2 mice 3 and 6 days after BLM-induced damage (Figure 2A ). Differential analyses revealed equivalent frequencies of macrophage, neutrophil, and lymphocyte subsets ( Figure 2B ). The only significant alteration was a decrease in the frequency of infiltrating eosinophils (representing ,3% of the infiltrate in WT mice and ,1% in Cd34 2/2 mice) 6 days after BLM challenge ( Figure 2B ). This reflects a documented role of CD34 in recruitment of eosinophils to the lung (14, 28) . We also observed similar levels of proinflammatory cytokines, IL-1b, IL-6, CXCL1, and TNF-a, in lung tissue of Cd34 2/2 and WT animals 6 days after damage ( Figure 2C ). In summary, because of the similar degree of inflammation, we conclude that differences in infiltrating inflammatory cells are unlikely to account for the increased mortality in BLM-treated Cd34 2/2 mice.
Morbidity within the first week of BLM treatment can also be attributed to exacerbated exudative responses during acute lung injury; such pathological features include disruption of endothelial and epithelial barriers, resulting in leakage of circulatory contents into the interstitium, and edema (22, 29) . We previously demonstrated increased vascular leak in lungs of Cd34 2/2 animals in a model of occupational asthma (18) . To evaluate CD34 function in the maintenance of vascular integrity in response to acute lung injury, we assessed vascular leak in WT and Cd34 2/2 mice 6 days after BLM exposure using a modified Miles assay (25, 26) . We found that Cd34 2/2 lung tissues displayed enhanced vascular leak, as measured by EBD extracted from the lung interstitium ( Figure 3A) . Moreover, we observed a strong correlation between weight loss and severity of vascular leak ( Figure 3B ).
In our evaluation of histological sections of hematoxylin and eosin-stained 1 (myeloid cells), lymphocyte antigen 6 complex, locus B (Ly6B) 1 (7/4) (neutrophils), CD11c 2 Sialic acid-binding immunoglobulin-type lectins (Siglec) F 1 (eosinophils), CD3e 1 (T lymphocytes), and B220 1 (B lymphocytes). *P , 0.05, Mann-Whitney test (n = 3 per PBS-treated group; n = 4-8 per BLM-treated group). Representative data from two independent experiments. (C) Quantification of IL-1b, IL-6, chemokine (C-X-C motif) ligand 1 (CXCL1), and TNF-a in BALF and lung homogenates of naive mice or BLM-treated mice 6 days after injury. Results represent the mean 6 SEM (n = 3-4 per PBS treated group; n = 6-7 per BLM-treated group). Representative data from two independent experiments are shown. lung tissues 6 days after BLM treatment, we did not observe profound differences in pathology associated with acute respiratory distress ( Figure E2) . This prompted us to analyze WT and Cd34 2/2 lungs at the ultrastructure level by transmission electron microscopy (TEM). Evaluation of PBStreated WT and Cd34 2/2 lungs did not reveal differences in the structure or localization of interstitial collagen and elastin, alterations in capillary endothelial or type 1 epithelial tight junctions, or cell-basal lamina interactions ( Figure E3 ). In contrast, 6 days after BLM challenge, we detected hypertrophy of type 1 pneumocytes in WT and Cd34 2/2 lung sections, which is indicative of injury ( Figures 4A-4F) . Strikingly, BLM-treated Cd34 2/2 lung specimens exhibit extensive edema within the interstitium and delamination of the endothelia, as evidenced by the exposed interstitial collagen and the disruption in the epithelial and capillary endothelial-basal lamina interactions. Thus, the ultrastructure data suggest that CD34 plays a role in maintaining appropriate structural integrity of the alveolar wall in response to acute damage. ORIGINAL RESEARCH (9, 30, 31) . To address this, we performed immunohistochemical analyses with antibodies against CD34 and used Cd34 2/2 lung samples as controls. CD34
CD34 Is
1 cells were detected in nearly all compartments, except the large airway epithelia, with minimal background in knockout-control sections ( Figure E4) . From the analysis of confocal z stack images, CD34 is expressed by podocalyxin 1 endothelia in addition to PDGFRa 1 and vimentin 1 fibroblast subsets ( Figures 5A and 5B ). Costaining with antibodies against E-cad and surfactant protein C indicate that CD34 is not expressed by epithelia in the distal airways or the bronchoalveolar duct junctions (BADJs), where CD34-expressing epithelial progenitors were previously reported ( Figure 5C ) (9) . This is consistent with flow cytometric data, which show that CD34 1 cells costain with the endothelialspecific antigen, CD31, and the majority of we find a lack of CD34 expression in sorted EpCAM 1 epithelial cells ( Figure 5D ). Pulmonary fibroblasts represent a heterogeneous population; studies indicate that lung PDGFRa 1 cells consist of desmin 1 lipofibroblasts that support pneumocyte maintenance in alveolosphere cultures and proliferate in response to BLM treatment (32, 33) . However, we saw equivalent expansion and proliferation of this fibroblast population in WT and Cd34 2/2 mice analyzed 6 days after BLM damage ( Figure 5E ). We conclude that CD34 is not expressed by lung epithelial progenitors and, although it is expressed by fibroblasts, loss of CD34 has no effect on the proliferative response of these cells or their ability to produce matrix in late-stage disease. Previously, we observed increased vascular leakage in Cd34 2/2 mice during autoimmune arthritis (34) and, thus, we hypothesize that this vascular cell intrinsic function of CD34 could contribute to the early mortality phenotype observed in the current study. To conclusively exclude the possibility that this enhanced mortality reflects a defective hematopoietic function for CD34, we generated BM chimeric mice with selective loss of CD34 in either the hematopoietic or nonhematopoietic compartments ( Figures 6A and 6D ). After BLM challenge by endotracheal or intravenous treatment, lethally irradiated Cd34 2/2 mice transplanted with WT BM exhibited a significantly higher incidence of mortality and weight loss compared with the WT recipients ( Figures 6B  and 6C ). Conversely, lethally irradiated WT CD45.1 animals transplanted with either Cd34 2/2 or WT BM and subsequently challenged with BLM displayed no significant differences in mortality rate or weight loss (Figures 6E and 6F) . These data suggest that the selective loss of CD34 from nonhematopoietic tissues contributes to increased sensitivity to BLM challenge. influenza infection, which induces extensive damage in the bronchioles and alveolar regions (1) . After infection, Cd34 2/2 mice displayed significantly greater weight loss than WT animals over the disease course ( Figure 7A) . Again, the overall inflammatory responses were similar in Cd34 2/2 and WT animals, as the numbers of inflammatory infiltrates in the airways were comparable at Days 7 and 12 after infection ( Figure 7B ). Moreover, differential analyses indicated that myeloid, neutrophil, eosinophil, and lymphocyte subsets were unaltered due to loss of CD34 ( Figure 7C) . Interestingly, however, we found greater evidence of pathology in lung sections of Cd34 2/2 animals; this was assessed by the quantification of tissue area displaying abnormal alveolar architecture and high cellular density, accompanied by loss of airway space (Figures 7D and 7E ). Although we found that Krt5-positive staining was restricted to the epithelial cells in the bronchioles of WT lung sections, Krt5-expressing clusters were more abundant, appearing in the peribronchial regions and in the distal airways of Cd34 2/2 lung tissues, arguing for greater disease severity. In summary, we find that loss of CD34 results in more pronounced sensitivity to influenza-induced tissue injury, as evidenced by unresolved tissue remodeling.
Early Mortality in BLM-Treated

Discussion
Inflammatory mediators have a clear association with the development and progression of lung fibrosis, particularly in cases arising from exposure to environmental irritants and infection (35) . Our previous work suggested a key role for CD34 in the recruitment of inflammatory subsets, and that Cd34 2/2 mice exhibit attenuated pathological features of lung or intestinal inflammation (14, 15, 18, 21) . However, the relevance of CD34 in responses to lung injury, remodeling, and fibrosis has not been examined. Given the importance of CD34 in mast cell and eosinophil trafficking, we postulated a function in fibrotic disease (12, 14, 17, 28) . The accumulation of eosinophils and mast cells in the lung has previously been associated with idiopathic pulmonary fibrosis. Elevated eosinophils in the BALF is associated with poor prognosis (36); moreover, pathological contributions of eosinophils to idiopathic pulmonary fibrosis have been attributed to the cytotoxic factors they produce (37, 38) , or the profibrogenic factors that induce excessive remodeling (39) (40) (41) . Although we did observe a reduced frequency of eosinophils recruited to the lung in Cd34 2/2 mice early after BLM treatment, this did not have a protective effect. Thus, in the BLM model, eosinophils appear to be largely dispensable. Although eosinophilia and Th2 cytokines have previously been reported to be promoters of BLM-induced fibrosis (39, 40, 42) , our findings are consistent with more recent studies demonstrating that the fibrosis is primarily Th17 driven, and independent of IL-13 signaling (43, 44) . Importantly, the profibrotic effects of IL-17A have been highlighted in several disease-associated contexts (45, 46) .
Instead, loss of CD34 renders mice extremely sensitive to BLM-induced mortality, with animals displaying microstructural loss of endothelial cell integrity and interstitial edema. Nearly all incidences of morbidity and mortality occur before the appearance of scarring in the lungs, and the late-phase fibrosis and tissue remodeling is equivalent in WT and Cd34 2/2 mice. Because the single-dose BLM treatment model is associated with a transient and self-limiting fibrotic response, we cannot rule out a more subtle effect of CD34 loss in more robust models of fibrosis (23) . Nevertheless, our data suggest that CD34 is dispensable for the debilitating production of matrix in response to lung injury, and that, instead, it plays a role during a transient window before the remodeling and fibrotic response. This result was confirmed in a second, influenza-driven model of lung injury, where tissue remodeling is a prominent feature. Here too, CD34 appears to be dispensable in the inflammatory response, but Cd34 2/2 mice displayed greater weight loss, and their lungs displayed a more pronounced pathology, accompanied by the appearance of Krt5 1 epithelial clusters in the bronchioles and in the distal airways. Although Krt5 1 epithelial progenitors are necessary for regeneration to restore gas exchange, their accumulation may be indicative of increased susceptibility to damage or unresolved tissue remodeling (47, 48) .
Previously, we have noted that loss of CD34 results in altered vascular integrity in a number of inflammatory settings, including autoimmune arthritis (34) , hypersensitivity pneumonitis (18) , and tumor formation (49). Because we observed no major differences in the number of BALF infiltrates or levels of proinflammatory cytokines in Cd34 2/2 and WT animals, our data suggest that the exacerbated interstitial edema observed in Cd34 2/2 animals is a cell-intrinsic defect of the endothelium. BM chimera experiments further support a nonhematopoietic origin of this phenotype, as the mortality occurred in the absence of CD34 on hematopoietic cells. Vascular integrity can be modulated by changes in junctional proteins that alter cell-cell interactions and integrin-dependent cell-matrix interactions (50) . Consistent with altered integrin-dependent adhesion, but normal cell junctions, TEM evaluation of BLM-challenged Cd34 2/2 lungs reveals extensive interstitial edema, yet the endothelial-endothelial junctional complexes remain intact. Thus, our data suggest that CD34 plays a role in maintaining the integrity of endothelial adhesion to the basal lamina.
In many ways, the decreased adhesion of Cd34 2/2 endothelia to basal lamina is counterintuitive. Previously, we have shown that CD34 and its close relative, podocalyxin, are heavily glycosylated and negatively charged sialomucins that provide an antiadhesive quality to hematopoietic cells, developing endothelia and epithelial tumor cells (12, 17, (51) (52) (53) . It is noteworthy, however, that we and others have found that the antiadhesive podocalyxin and active integrin signaling cooperate to facilitate the establishment of distinct, integrin-linked, basolateral/matrix bound surfaces and integrin-free, podocalyxin-rich, nonadhesive apical domains (12, 25, 51, 54) . Thus, loss of CD34 would weaken vessel integrity, an effect that we observe via TEM analyses of Cd34 2/2 endothelia after BLM treatment. Integrindependent adhesion is primarily regulated by changes in conformation (affinity) and activation-dependent clustering (avidity) (55) . Therefore, we speculate that loss of CD34 prevents integrins from adopting an active conformation or limits the ability of integrins to effectively cluster at the basolateral domains and promote adhesion. Intriguingly, we have found that overexpression of CD34-type proteins in epithelial cell lines tends to facilitate segregation of apical and basolateral proteins and the establishment of these domains in cells undergoing primary adhesion (52) . Moreover, cells that lack these proteins exhibit a delay in the recruitment of integrins to basolateral domains. Thus, delamination of endothelia observed in the current study may reflect an impaired ability to properly localize active integrins to the basal lamina rather than a loss of integrin expression per se. Future studies aimed at detailed structure/function analyses may provide mechanistic insights into the functional domains of CD34 required for modulating integrin sorting and function.
CD34 is a marker for progenitor subsets of nonhematopoietic cell types, including muscle satellite cells, hair follicle stem cells, and mesenchymal progenitors (5) (6) (7) (8) . It has been postulated that its utility as an enrichment marker for undifferentiated cells could be extended to epithelial progenitors of the lung, namely bronchoalveolar stem cells. These cells are proposed to exist at BADJs and have the potential to give rise to terminal epithelial cells of the bronchioles and distal airways (9) . However, subsequent studies have reported that epithelial lineages lack CD34 expression (31, 56, 57 (32, 58) . Previously, we found that CD34 is dispensable for normal function of FAPs (59) . This is consistent with our observations that lung FAPs, in an acute response to BLM, expand in similar numbers and display similar rates of proliferation in WT and Cd34 2/2 animals. However, we may not formally rule out an additional role for CD34 in lung FAPs; the intimate association of these cells with the endothelium, and their known role in tissue repair and matrix production, highlights the importance of endothelial-FAP cell cross-talk.
In summary, our data suggest that vascular CD34 serves a protective function during lung injury by enhancing the endothelial-matrix interactions, thereby preventing delamination and reducing permeability. Future structural and functional studies designed to identify the requisite domains of the molecule could offer insights into how this function could be modulated to treat pulmonary edema. n Author disclosures are available with the text of this article at www.atsjournals.org.
